AI is beginning to transform biologics discovery. The power of algorithms used in biologics discovery has increased over the last decade, and today between 50 and 60 AI-enabled biologics are in different stages of discovery, preclinical and clinical development. We expect the number of AI-enabled biologics to continue to grow rapidly, driven by advances in AI technology and algorithms, growing computing power, increasing availability of data, and evolving discovery workflows. We show that the volume of data used for training algorithms in biologics discovery is increasing exponentially over time, a trend reminiscent of Moore’s Law in computer technology.
Artificial intelligence (AI) and machine learning are revolutionizing drug discovery. Over the last five to ten years the main focus has been on small molecules, where we are seeing strong growth in the number of compounds discovered using AI technologies.
In parallel, but less well-known, AI is beginning to transform other areas of drug discovery, most importantly biologics (protein and...